Trial Profile
A Phase Ib, Multicenter, Randomized Study to Evaluate the Pharmacokinetics, Efficacy and Safety of TQB2450 Combined With or Without Anlotinib in Patients With Advanced Non-small Cell Lung Cancer NSCLC
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 24 May 2023
Price :
$35
*
At a glance
- Drugs Benmelstobart (Primary) ; Catequentinib (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- Sponsors Chia Tai Tianqing Pharmaceutical Group
- 24 May 2023 Status changed from recruiting to completed.
- 19 Apr 2023 updated PFS, OS and safety results presented at the 114th Annual Meeting of the American Association for Cancer Research
- 29 Oct 2019 Status changed from not yet recruiting to recruiting.